Business Context and Reporting Period
This Form 6-K filing covers the month of February 2012 for Prana Biotechnology Limited (ASX: PBT), an Australian biotechnology company. The registrant is a foreign private issuer filing under Rule 13a-16. The document serves as a notice under Section 708A(5) of the Corporations Act regarding a specific securities issuance.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to a specific capital raise event:
- Securities Issued: 1,250,030 Ordinary Fully Paid Shares.
- Issue Date: February 8, 2012.
- Total Proceeds: AUD$ 205,833.
- Implied Issue Price: Approximately AUD$ 0.165 per share (calculated from total proceeds and share count).
Material Changes
The primary material change reported is the issuance of 1,250,030 new ordinary shares without prior disclosure to investors under Part 6D.2 of the Corporations Act. The company has applied to the Australian Securities Exchange (ASX) for quotation of these shares. The filing confirms compliance with Chapter 2M and Section 674 of the Corporations Act as of the notice date.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors beyond the regulatory disclosure of the share issuance. No unusual items or contingencies are described in the text provided.
Investor Verification Checklist
- Verify the final listing status of the 1,250,030 shares on the ASX.
- Confirm the exact per-share issue price and the identity of the investors who received the shares.
- Review the company's latest audited financial statements to assess the impact of the AUD$ 205,833 capital raise on overall liquidity.
- Check for any subsequent filings regarding the use of proceeds from this issuance.